Compare WILC & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WILC | CNTX |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 351.4M | 283.9M |
| IPO Year | 2001 | 2021 |
| Metric | WILC | CNTX |
|---|---|---|
| Price | $25.20 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 1.4K | ★ 947.7K |
| Earning Date | 03-24-2026 | 03-23-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.54 | $0.49 |
| 52 Week High | $31.16 | $3.62 |
| Indicator | WILC | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 43.95 |
| Support Level | $19.68 | $2.07 |
| Resistance Level | $26.26 | $2.72 |
| Average True Range (ATR) | 0.56 | 0.30 |
| MACD | -0.09 | -0.09 |
| Stochastic Oscillator | 0.00 | 0.69 |
G. Willi-Food International Ltd is a company engaged in high-quality, great-tasting kosher food products. The Company is engaged, directly and through subsidiaries, with one segment Import-export, marketing, and distribution of food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Dried Fruit, Nuts and Beans, and Other Products. Its brands include Willi-Food, Euro European Dairies, Donna Rozza, Manchow, Gold Frost, Tifeeret, The Chef Dish, Art Coffe, Mr. Chang, Muchi, Euro Butter, Euro Spread, Euro Cheese, Euro Cream, Euro Dessert, Euro Veg, Ha-Bulgaria, Gelato, and Emma.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.